MRVI Stock Overview
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.67 |
| 52 Week High | US$16.62 |
| 52 Week Low | US$4.52 |
| Beta | 0.0060 |
| 1 Month Change | -9.66% |
| 3 Month Change | 24.72% |
| 1 Year Change | -41.98% |
| 3 Year Change | -79.75% |
| 5 Year Change | n/a |
| Change since IPO | -74.30% |
Recent News & Updates
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Recent updates
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price
Oct 07Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Worth US$41.7 Based On Its Intrinsic Value?
Jul 01Maravai LifeSciences: The Future Beyond Covid Vaccines
Jun 29Need To Know: Analysts Are Much More Bullish On Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
May 13Shareholder Returns
| MRVI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.8% | 4.1% | 1.2% |
| 1Y | -42.0% | 4.7% | 24.9% |
Price Volatility
| MRVI volatility | |
|---|---|
| MRVI Average Weekly Movement | 19.7% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: MRVI's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 650 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI fundamental statistics | |
|---|---|
| Market cap | US$1.94b |
| Earnings (TTM) | -US$119.03m |
| Revenue (TTM) | US$288.95m |
3.5x
P/S Ratio-8.5x
P/E RatioIs MRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI income statement (TTM) | |
|---|---|
| Revenue | US$288.95m |
| Cost of Revenue | US$148.74m |
| Gross Profit | US$140.20m |
| Other Expenses | US$259.23m |
| Earnings | -US$119.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 48.52% |
| Net Profit Margin | -41.19% |
| Debt/Equity Ratio | 66.4% |
How did MRVI perform over the long term?
See historical performance and comparison